{
  "id": "mhgap#risk_safety_d39c54e0",
  "content": "anxiety symptoms in adults with anxiety disorders was limited and indicated they did not demonstrate\n(GAD or panic disorder) using either psychological a significant effect relative to placebo.\ninterventions or antidepressant medicines and y TCAs are generally less well tolerated than SSRIs\nno consistent difference between the two in and therefore are recommended for consideration in\ndirect comparisons. cases where SSRIs are not available for adults with\ny See recommendation ANX2 for further detail on panic disorder.\npsychological interventions. y Antidepressants should only be offered in those\ncontexts where health workers are competent (e.g.\nRemarks\nqualified, trained and supervised) to prescribe\ny SSRIs for panic disorder examined included:\npsychotropic medicines.\ncitalopram, escitalopram, fluoxetine, fluvoxamine,\ny Psychological interventions should be offered only\nparoxetine and sertraline. Individual analyses\nin contexts where individuals are competent (e.g.\nindicated sertraline and escitalopram may be the\nqualified, trained and supervised) to provide them\nmost efficacious with lowest risk of adverse effects.\nand demonstrate necessary competencies to do so.\nFluvoxamine, paroxetine and fluoxetine indicated\ny In resource-constrained settings, antidepressants\nfavourable efficacy but higher risk of adverse events.\n(SSRIs for GAD; SSRIs as first-line treatment and then\nCitalopram indicated minimal efficacy and high risk",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "work",
      "risk_safety",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety anxiety symptoms in adults with anxiety disorders was limited and indicated they did not demonstrate\n(GAD or panic disorder) using either psychological a significant effect relative to placebo.\ninterventions or antidepressant medicines and y TCAs are generally less well tolerated than SSRIs\nno consistent difference between the two in and therefore are recommended for consideration in\ndirect comparisons. cases where SSRIs are not available for adults with\ny See recommendation ANX2 for further detail on panic disorder.\npsychological interventions. y Antidepressants should only be offered in those\ncontexts where health workers are competent (e.g.\nRemarks\nqualified, trained and supervised) to prescribe\ny SSRIs for panic disorder examined included:\npsychotropic medicines.\ncitalopram, escitalopram, fluoxetine, fluvoxamine,\ny Psychological interventions should be offered only\nparoxetine and sertraline. Individual analyses\nin contexts where individuals are competent (e.g.\nindicated sertraline and escitalopram may be the\nqualified, trained and supervised) to provide them\nmost efficacious with lowest risk of adverse effects.\nand demonstrate necessary competencies to do so.\nFluvoxamine, paroxetine and fluoxetine indicated\ny In resource-constrained settings, antidepressants\nfavourable efficacy but higher risk of adverse events.\n(SSRIs for GAD; SSRIs as first-line treatment and then\nCitalopram indicated minimal efficacy and high risk Lo âu symptoms in adults with lo âu disorders was limited and indicated they did not demonstrate\n(gad or panic disorder) using either psychological a significant effect relative to placebo. interventions or antidepressan..."
}